Obsessive-Compulsive Disorder Clinical Trial
Official title:
Open -Label Trial on the Effects of Memantine in Adults With Obsessive-Compulsive Disorder After a Single Ketamine Infusion
Obsessive-compulsive disorder (OCD) is a common psychiatric illness that affects up to 2-3%
of the population. People with OCD experience anxiety-provoking, intrusive thoughts, known
as obsessions, and feel compelled to perform repetitive behaviors, or compulsions. The only
medications proven effective for OCD are serotonin reuptake inhibitors (SRIs), but even with
SRI treatment, most patients continue to experience significant OCD symptoms, impaired
functioning, and diminished quality of life. Recent evidence suggest that a different
neurotransmitter, glutamate, may contribute to the symptoms in OCD. Medications that target
glutamate hold promise for ameliorating symptoms for those patients continuing to suffer
from OCD. In this study the investigators are recruiting patients to receive the drug
memantine, which is thought to modulate the neurotransmitter glutamate, added to whatever
other OCD medications they are taking.
Open label memantine will be titrated in 5mg increments weekly to target dose of 10mg po bid
for up to 6 weeks. Memantine will be continued to 12 weeks in those with treatment
response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV
ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks
of memantine).
see above ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04934007 -
Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder
|
N/A | |
| Recruiting |
NCT04071990 -
Family Involvement in CBGT of OCD: a Randomized Controlled Trial
|
N/A | |
| Completed |
NCT02541968 -
Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder
|
N/A | |
| Recruiting |
NCT05651295 -
A Precision Medicine Approach to Target Engagement for Emotion Regulation
|
N/A | |
| Recruiting |
NCT05391503 -
Light Therapy for Obsessive-compulsive Disorder (OCD)
|
N/A | |
| Recruiting |
NCT04539951 -
Pragmatic Trial of Obsessive-compulsive Disorder
|
Phase 2 | |
| Completed |
NCT03416504 -
Methods for Managing Intrusive Thoughts
|
N/A | |
| Not yet recruiting |
NCT06029738 -
Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD
|
N/A | |
| Recruiting |
NCT02844049 -
European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS
|
N/A | |
| Terminated |
NCT02909660 -
What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder
|
N/A | |
| Completed |
NCT02911324 -
Cannabinoid Medication for Adults With OCD
|
Phase 1/Phase 2 | |
| Completed |
NCT02217995 -
Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients
|
N/A | |
| Terminated |
NCT02234011 -
A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder
|
Phase 2 | |
| Withdrawn |
NCT01953042 -
Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders
|
N/A | |
| Completed |
NCT02655926 -
Deep Brain Stimulation for Severe Obsessive Compulsive Disorder
|
N/A | |
| Terminated |
NCT00758966 -
Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder
|
Phase 2 | |
| Completed |
NCT00742664 -
Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project
|
Phase 1/Phase 2 | |
| Completed |
NCT04919785 -
Deep Brain Stimulation in Severe Obsessive-compulsive Disorder
|
N/A | |
| Completed |
NCT00523718 -
Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
|
Phase 2 | |
| Completed |
NCT00074815 -
Treatment of Obsessive Compulsive Disorder in Children
|
Phase 3 |